Pethidine

Discovery

Pethidine was synthesized in 1938 by Otto Eisleb at IG Farben in Germany — he was searching for antispasmodics, not analgesics.^[1] Otto Schaumann identified the opioid properties and published the finding under the trade name "Dolantin."^[1] That accidental discovery established the 4-phenylpiperidine scaffold that later produced fentanyl and every subsequent phenylpiperidine opioid.^[5]

Clinical dominance

Launched in the US as Demerol in 1943,^[2] pethidine rapidly became the dominant hospital opioid. By 1975, approximately 60% of US physicians named it their preferred opioid for acute pain.^[2]

Decline and modern status

In the 1980s, case reports documented seizures in cancer patients,^[4] kidney failure patients,^[6] and those with sickle cell disease^[7] — all caused by normeperidine buildup. Pethidine was removed from the WHO Essential Medicines List by 2003,^[3] and the 2023 AGS Beers Criteria classified it as a drug to always avoid in older adults.^[8] It retains limited use for post-anaesthetic shivering^[9] and labour analgesia in some countries, though evidence suggests inferior efficacy compared to alternatives.^[10]

Structural class

Pethidine is the prototype of the 4-phenylpiperidine opioid family — a class defined by a phenyl ring attached to a piperidine ring.^[5] Its relatively simple structure proved that the complex ring systems of morphine were unnecessary for opioid activity, reshaping analgesic drug design. Systematic modification of the pethidine scaffold produced fentanyl and the entire fentanyl family.

Molecular properties

The pharmaceutical form is the hydrochloride salt — a white crystalline powder with a melting point of 187–188°C.^[11] Pethidine has no chirality centre and is used clinically as a single constitutional isomer.

Mechanism of action

Pethidine is a full agonist at opioid receptors, producing pain suppression, sedation, euphoria, and respiratory depression.^[5][3] It also blocks serotonin reuptake — a property absent from morphine and fentanyl. Combining it with MAOIs or SSRIs can trigger dangerous serotonin overload, because those drugs prevent serotonin from breaking down normally.^[12][13]

Additional activity produces a mild stimulant quality from dopamine and NET blockade,^[3] local anaesthetic effects from sodium channel blockade,^[13] anticholinergic activity causing a faster heartbeat and dilated pupils,^[5][13] and histamine release causing itching.^[13]

Pharmacokinetics

Oral bioavailability is around 50% in healthy adults, rising to 80–90% in liver disease.^[2][14] The liver converts pethidine into normeperidine — a metabolite with half its pain-relieving power but twice its seizure-inducing power.^[3] Normeperidine takes 8–21 hours to clear^[3][2] — far longer than pethidine itself — so it accumulates with repeated doses, especially when kidneys are impaired.

Where it acts

Opioid receptor activation in the brain's reward circuitry releases dopamine, producing euphoria and reinforcing repeated use.^[15] The same receptors in the brainstem and spinal cord suppress pain signals; sodium channel blockade at the spinal level adds an additional layer of pain suppression.^[13] Pethidine also activates a different type of opioid receptor in the brain's temperature-regulation centre — which explains its unique ability to stop post-anaesthetic shivering.^[9]

Tolerance and adaptation

Dopamine and NET blockade^[3] may amplify the rewarding effect beyond what morphine-type opioids produce. Chronic opioid receptor activation makes receptors less responsive over time,^[15] and as doses escalate, normeperidine accumulates — so seizure risk climbs as pain control weakens. Serotonin reuptake blockade also raises serotonin levels in key brain circuits,^[12] creating dangerous conditions when combined with monoamine oxidase inhibitors or SSRIs.^[16]

Toxicity

Pethidine carries high acute and chronic toxicity. It is more dangerous than most opioids because of two unique liabilities that morphine, fentanyl, and hydromorphone do not share: a neurotoxic breakdown product and the ability to trigger serotonin overload.

safety citation needed No human lethal dose has been established.

Documented consequences include tremors and muscle jerks in patients on high cumulative doses,^[4] seizures in kidney failure,^[6] and seizures with agitation in sickle cell disease.^[7] Risk factors include cumulative doses above 600 mg per 24 hours, use beyond 48 hours, kidney impairment, and older age.

Psychological Risks

Pethidine carries the standard psychological risks of opioids: euphoria driving psychological dependence, cognitive impairment during intoxication, and compulsive drug-seeking. In older adults, it causes higher rates of confusion and delirium than alternative opioids.^[8][19]

Normeperidine buildup adds a distinct psychological toxicity — agitation, irritability, and disorientation that can progress to paranoid delirium.^[4] This state can be mistaken for undertreated pain, which prompts dose increases that worsen the underlying toxicity.

Tolerance & Dependence

Tolerance develops through standard opioid mechanisms^[15] and physical dependence follows quickly with regular use. Withdrawal follows the general opioid pattern — muscle aches, sweating, diarrhea, insomnia, and low mood — with the additional concern that declining normeperidine levels may produce tremors and seizures in heavy users.

Cross-tolerance to other opioids is present but incomplete. Reduced doses are used when switching.^[20] Dependence liability is high, reflected in Schedule II (US) and Class A (UK) classification.

Drug Interactions

The MAOI–pethidine combination is an absolute contraindication — the most dangerous drug interaction in opioid pharmacology. It can produce either serotonin syndrome (overheating, rigidity, involuntary contractions, death) or opioid depression (coma, respiratory failure, cardiovascular collapse).^[18][13] The risk persists for 14 days after stopping an MAOI. SSRIs combined with pethidine also produce serotonin syndrome.^[12]

Alcohol, benzodiazepines, other opioids, barbiturates, GHB, and GBL add to respiratory depression.^[3] Drugs that slow liver metabolism — ketoconazole, ritonavir, and grapefruit juice — raise pethidine blood levels to dangerous concentrations.^[3] Mixed opioid agonist-antagonists such as buprenorphine can trigger withdrawal in dependent individuals.^[3]

Contraindications

Absolute:

• MAOI use within the preceding 14 days^[18][13]
• Severe kidney impairment — normeperidine accumulation produces seizures not reversible by naloxone^[6]
• Use exceeding 48 hours — normeperidine accumulates regardless of kidney function^[3]

Relative:

• Older adults — 2023 AGS Beers Criteria: always avoid^[8]
• Liver impairment — bioavailability rises to 80–90% and half-life doubles^[14]
• Seizure disorders — normeperidine lowers seizure threshold
• Sickle cell disease — documented normeperidine toxicity^[7][21]
• Concurrent SSRI use — serotonin syndrome risk^[12]
• Concurrent CYP3A4 inhibitors — elevated blood levels^[3]

Pethidine is internationally controlled under the UN Single Convention on Narcotic Drugs (1961) as a Schedule I substance, requiring all signatory nations to implement domestic controls.^[2]